NTN1 and cancer: Based on the causative role of Netrin-1 in cancer pathogenesis and extensive studies showing its efficiency as a therapeutic target, a monoclonal antibody (NP137) that targets Netrin-1 to disrupt its interaction with the UNC5B receptor has been developed and is currently receiving clinical phase 1 trial (NCT02977195) to evaluate safety and efficacy (Grandin et al., 2016; Cassier et al., 2023).